Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520768 | 0.85 | TLR2 (0.31) | TLR2 | |
| SCHEMBL1887227 | 0.84 | NOS2 (0.40) | TLR2PRCPCYP1A2CYP3A4CYP2D6 | |
| Alanine SCHEMBL5970554 | 0.83 | TLR2 (0.36) | TLR2PRCPCYP1A2CYP3A4CYP2D6 | |
| Leucine SCHEMBL6463328 | 0.83 | SLC7A5 (0.44) | TLR2PRCPCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2043828 | 0.83 | NOS2 (0.37) | TLR2PRCPCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8815155 | 0.82 | TLR2 (0.31) | TLR2MEN1KMT2A | |
| Proline SCHEMBL8582773 | 0.81 | TLR2 (0.34) | TLR2PRCPDPP7 | |
| Proline SCHEMBL7043240 | 0.81 | NOS2 (0.33) | PRCPCYP1A2CYP3A4CYP2D6CYP2C19 | |
| Glutamine SCHEMBL1304983 | 0.80 | KMT2A (0.43) | PRCPCYP1A2CYP3A4CYP2D6CYP2C19 | |
| Proline SCHEMBL140698 | 0.79 | TLR2 (0.34) | TLR2PRCPCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143958-A1 | METHOD FOR SEPARATION OF SPERM WITH UNDAMAGED INTACT HEADS FROM SPERM WITH DAMAGED HEADS AND SOMATIC CELLS | BIOTECHNOLOGICKY USTAV AV CR, V. V. I. (CZ) | 2021-07-22 | — | — | WO | disclosed |
| WO-2017174783-A1 | IDENTIFICATION OF CANDIDATE ANTICANCER DRUGS BASED ON RETINOBLASTOMA PHOSPHORYLATION AT SER249/THR252 | UNIVERSITAT POMPEU FABRA (ES) | 2017-10-12 | — | — | WO | disclosed |
| US-8877896-B2 | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders | TUFTS UNIVERSITY (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130149373-A1 | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders | TUFTS UNIVERSITY (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2566498-A1 | COMPOUNDS, MEDICAMENTS AND METHODS OF TREATMENT FOR HELICOBACTER PYLORI INFECTION. | Karolinska Institutet Innovations AB (SE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2012016162-A2 | COMPOSITIONS, METHODS AND KITS FOR MODELING, DIAGNOSING, AND TREATING COMPLEMENT DISORDERS | TUFTS UNIVERSITY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011139226-A1 | COMPOUNDS, MEDICAMENTS AND METHODS OF TREATMENT FOR HELICOBACTER PYLORI INFECTION. | KAROLINSKA INSTITUTET INNOVATIONS AB (SE) | 2011-11-10 | — | — | WO | disclosed |
| US-20100311726-A1 | REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR | NIH - DEITR | 2010-12-09 | — | — | US | disclosed |
| EP-0911390-B1 | Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease | MAX PLANCK GESELLSCHAFT (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20090162336-A1 | Novel Tools for the Diagnosis and Treatment of Alzheimer's Disease | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNGDER WISSENSCHAFTEN, E.V. (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20020188106-A1 | Novel tools for the diagnosis and treatment of Alzheimer's disease | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN, E.V. | 2002-12-12 | — | — | US | disclosed |
| US-6200768-B1 | DETECTING COMPOUNDS EFFICIENT IN THE DISSOLUTION OF AN ALZHEIMER'S PROTEIN; INCUBATE PREFERENTIAL PROTEIN WITH KINASE, MONITOR HELIX FORMATION, INCUBATE WITH MODULATOR AND DETECT BLOCKING ACTION BY MODULATOR | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-0911398-A2 | Phosphorylation epitopes of Tau protein for the diagnosis and treatment of Alzheimer's disease | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1999-04-28 | — | — | EP | disclosed |
| EP-0911390-A2 | Protein kinases as tools for the diagnosis and treatment of Alzheimer's disease | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1999-04-28 | — | — | EP | disclosed |
| EP-0909814-A2 | Use of protein kinases for the diagnosis and treatment of Alzheimer's disease | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1999-04-21 | — | — | EP | disclosed |
| EP-0791067-A2 | PROTEIN KINASE NPK-110 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996013592-A2 | PROTEIN KINASE NPK-110 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1996-05-09 | — | — | WO | disclosed |
| EP-0618968-A1 | TOOLS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993011231-A1 | TOOLS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1993-06-10 | — | — | WO | disclosed |
| EP-0544942-A1 | Novel tools for the diagnosis and treatment of Alzheimer disease | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1993-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311726-A1 | REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR | APP, BACE1, APBA1 | TLR2 3873/4885PRCP 1576/4885CYP1A2 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.